Journal: Discovery Medicine

Article Title: Artesunate Inhibits Lipid Accumulation and Inflammation by Regulating the NLRP3 Inflammasome in Nonalcoholic Fatty Liver Disease

doi: 10.24976/discov.med.202436181.36

Figure Lengend Snippet: Fig. 1. Effect of artesunate (ART) on cell viability in LO2 cells after oleic acid (OA) treatment. (A) Effect of OA at different

Article Snippet: Human normal liver cells LO2 (TongPai, Shanghai, China) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (CM10041, MACGENE, Beijing, China) supplemented with 10% fetal bovine serum (FBS, FCS500, EXcellBio, Shanghai, China) and 100 U/mL penicillin-streptomycin (P1400, Solarbio, Beijing, China).

Techniques:

Journal: Discovery Medicine

Article Title: Artesunate Inhibits Lipid Accumulation and Inflammation by Regulating the NLRP3 Inflammasome in Nonalcoholic Fatty Liver Disease

doi: 10.24976/discov.med.202436181.36

Figure Lengend Snippet: Fig. 2. ART restrained lipid accumulation in LO2 cells after OA treatment. (A) Lipid accumulation was demonstrated by oil red O staining (n = 3) (scale bar: 50 µm). (B) Effect of ART on triglycerides (TG) in LO2 cells after OA treatment (n = 3). (C) Effect of ART

Article Snippet: Human normal liver cells LO2 (TongPai, Shanghai, China) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (CM10041, MACGENE, Beijing, China) supplemented with 10% fetal bovine serum (FBS, FCS500, EXcellBio, Shanghai, China) and 100 U/mL penicillin-streptomycin (P1400, Solarbio, Beijing, China).

Techniques: Staining

Journal: Discovery Medicine

Article Title: Artesunate Inhibits Lipid Accumulation and Inflammation by Regulating the NLRP3 Inflammasome in Nonalcoholic Fatty Liver Disease

doi: 10.24976/discov.med.202436181.36

Figure Lengend Snippet: Fig. 3. ART decreased the secretion of pro-inflammatory factors in OA treated LO2 cells. (A) Effect of ART on tumor necrosis

Article Snippet: Human normal liver cells LO2 (TongPai, Shanghai, China) were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (CM10041, MACGENE, Beijing, China) supplemented with 10% fetal bovine serum (FBS, FCS500, EXcellBio, Shanghai, China) and 100 U/mL penicillin-streptomycin (P1400, Solarbio, Beijing, China).

Techniques:

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: NAFLD models established to investigate changes in AC012668 expression. (a) Heat map of differentially expressed lncRNAs in NAFLD. (b) Cell viability and (c and d) apoptosis of LO2 cells treated with FFA. (e and f) Oil-Red O staining image and TG level in the liver tissues of HFD mice. (g) AC012668 expression levels in the liver tissues of HFD mice. (h) Expression of AC012668 in FFA-treated cells. *P < 0.05 vs. control; **P < 0.01 vs. control

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Expressing, Staining

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: AC012668 suppresses TG/lipid accumulation and lipogenesis in LO2 cells. (a) AC012668 expression level in FFA-treated LO2 cells transfected with the AC012668 overexpression plasmid. (b) mRNA and (c and d) protein expression levels of SCD1, SREBP1 , and FAS in FFA-treated LO2 cells. (e) TG level and (f) Oil-Red O staining in FFA-treated LO2 cells. *P < 0.05 vs. pcDNA3.1 or AC012668.

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Expressing, Transfection, Over Expression, Plasmid Preparation, Staining

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: miR-380-5p directly targets AC012668 . (a) Wild and mutant types of AC012668 reporters labeled with luciferase. (b) Expression levels of miR-380-5p in AC012668 -enhanced/-inhibited LO2 cells. (c) Relative luciferase activities in wild-type and mutant AC012668 groups compared with the mimic negative control group. (d) Relative enrichment of AC012668 in the biotinylated miR-380-5p group. (e) AC012668 expression levels in the liver tissues of HFD mice. (f) Expression level of miR-380-5p in LO2 cells treated with 1 mM FFA. *P < 0.05 vs. biotin-NC; **P < 0.01 vs. si-NC, vector, mimic NC, or control

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Mutagenesis, Labeling, Luciferase, Expressing, Negative Control, Plasmid Preparation

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: miR-380-5p promotes TG/lipid accumulation and lipogenesis in LO2 cells transfected with AC012668 . (a) AC012668 expression detected using reverse transcription-quantitative polymerase chain reaction. (b) mRNA and (c and d) protein levels of SCD1, SREBP1 , and FAS . (e) TG level and (f) lipid deposition. *P < 0.05 vs. AC012668 + mimic NC; **P < 0.01 vs. vector

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Transfection, Expressing, Real-time Polymerase Chain Reaction, Plasmid Preparation

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: LRP2 is a target of miR-380-5p . (a) Wild and mutant types of LRP2 reporters labeled with luciferase. (b) mRNA expression of LRP2 in FFA-treated LO2 cells transfected with the miR-380-5p mimic or inhibitor. (c) Relative luciferase activities in wild-type and mutant LRP2 groups compared with the mimic negative control group. (d) Relative enrichment of LRP2 in the biotinylated miR-380-5p group. (e) AC012668 expression levels in the liver tissues of HFD mice. (f) Expression level of LRP2 in FFA-treated LO2 cells. *P < 0.05 vs. biotin-NC; **P < 0.01 vs. inhibitor NC, mimic NC, or control

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Mutagenesis, Labeling, Luciferase, Expressing, Transfection, Negative Control

Journal: Bioengineered

Article Title: Long non-coding RNA AC012668 suppresses non-alcoholic fatty liver disease by competing for microRNA miR-380-5p with lipoprotein-related protein LRP2

doi: 10.1080/21655979.2021.1960463

Figure Lengend Snippet: Effects of LRP2 knockdown on TG/lipid accumulation and lipogenesis in miR-380-5p -inhibited LO2 cells. (a) miR-380-5p expression level in LO2 cells cotransfected with the miR-380-5p inhibitor and si-LRP2 . (b) mRNA and (c and d) protein levels of SCD1, SREBP1 , and FAS in the miR-380-5p inhibitor- and si-LRP2 -cotransfected cells. (e) TG level and (f) lipid deposition in the miR-380-5p inhibitor- and si-LRP2 -cotransfected cells. *P < 0.05 vs. control or miR-380-5p mimic + si-NC

Article Snippet: Normal human hepatocyte lines LO2 were purchased from Biowit Biotechnology Inc. (cat no. C0009).

Techniques: Expressing